Is there a role for molecular prognostic factors in the clinical management of ductal carcinoma in situ (DCIS) of the breast?

Radiotherapy and Oncology

Volumn 55, Issue 2, 2000, Pages 95-99

  Zaugg, Kathrin ^a   Bodis, Stephan ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Apoptosis; Breast cancer; Ductal carcinoma in situ; Prognostic factors

Indexed keywords

CYCLIN A; CYCLIN D; CYCLIN D1; CYCLIN DEPENDENT KINASE; DOXORUBICIN;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CARCINOGENESIS; CARCINOMA IN SITU; CELL CYCLE; HUMAN; MAMMOGRAPHY; ONCOGENE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

APOPTOSIS; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; PROGNOSIS; RECEPTORS, GROWTH FACTOR; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034193476     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(99)00186-3     Document Type: Article

References (49)

1. Aas T, Borresen A-L, Geisler S, et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat. Med. 1996;2:811-813.
2. Bergh J, Norberg T, Sjögren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy, Nat. Med. 1995;1:1029-1034.
3. Bodis S, Siziopikou KP, Schnitt SJ, Harris JR, Fisher DE. Extensive apoptosis in ductal carcinoma in situ of the breast. Cancer 1996;77: 1831-1835.
4. Chappell SA, Walsh T, Walker RA, Shaw JA. Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor gene correlates with poor differentiation in early breast carcinomas. Br. J. Cancer 1997;76:1558-1561.
5. Coene ED, Schelfhout V, Winkler RA, et al. Amplification units and translocation at chromosome 17q and c-erbB-2 overexpression in the pathogenesis of breast cancer. Virchows Arch. 1997;430(5):365-372.
6. Consensus Conference Committee. Consensus conference on the classification of ductal carcinoma in situ. Cancer 1997;80:1798-1802.
7. De Vita VT. Cancer, Principles and practice of oncology, 5th ed. USA: Lippincott-Raven, 1996.
8. Ernster V, Barclay J, Kerlikowske K, Grady D, Henderson C. Incidence of and treatment for ductal carcinoma in situ of the breast. J. Am. Med. Assoc. 1996;275(12):913-918.
9. Fisher B, Constantino J, Redmond C. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N. Engl. J. Med. 1993;328:1581-1586.
10. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994;78:539-554.
11. Fisher ER, Costantino J, Fisher B, Palekar AS, Redmond C, Mamounas E. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) protocol B-17. Cancer 1995;75:1310-1319.
12. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J. Clin. Oncol. 1992;10: 1049-1056.
13. Harris JR, Lippman ME, Veronesi U, Willet W. Breast cancer, part two, N. Engl. J. Med. 1992;327:390-398.
14. Hetelekidis S, Schnitt SJ, Morrow M, Harris JR. Management of ductal carcinoma-in-situ. Cancer J. Clin. 1995;45(4):244-253.
15. Hoensuu H, Pylkkanen L, Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am. J. Pathol. 1992;145:1191-1198.
16. Holland R, Peterse JL, Millis RR, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin. Diagn. Pathol. 1994;11(3): 167-180.
17. Jansson T, Inganäs M, Sjögren S, et al. P53 status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J. Clin. Oncol. 1995;13:2745-2751.
18. Lagios MD, Westdahl PR, Margolin FR, Rose MR. Ductal carcinoma in situ: relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures, Cancer 1982;50:1309-1314.
19. Lipponen P, Aaltomaa S, Kosma VM, Syrjaenen K. Apoptosis in breast cancer is related to histopathological characteristics and apoptosis. Eur. J. Cancer 1994;30A:2068-2073.
20. Lodato RF, Maguire Jr HC, Greene MI, Weiner DB, LiVolsi VA. Immunohistochemical evaluation of c-erbB-2 oncogene expression in mammary ductal carcinoma in situ. Mod. Pathol. 1990;3:449-454.
21. Lukas J, Groshen S, Saffari B, et al. WAF1/Cip+ gene polymorphism and expression in carcinomas of the breast, ovary and endometrium, Am. J. Pathol. 1997;150(1):167-175.
22. Mamouras E, Fisher B, Dingam J, et al. Effect of breast irradiation following lumpectomy in intraductal carcnioma (DCIS): updated results from NSABP B-17. Proc. Sco. Surg. Oncol. 1997;50:7.
23. Millikan R, Hulka B, Zhang Y, et al. P53 mutations in benign breast tissue. J. Clin. Oncol. 1995;13:2293-2300.
24. Moore E, Magee H, Coyne J, Gorey T, Dervan PA. Widespread chromosomal abnormalities in high-grade ductal carcinoma in situ of the breast. Comparative genomic hybridization study of pure high-grade DCIS, J. Pathol. 1999;187:403-409.
25. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. N. Engl. J. Med. 1997;337:949-955.
26. Page DL. Ductal carcinoma in situ of the breast: understanding the misunderstood stepchild (Editorial). J. Am. Med. Assoc. 1996;275 (12):948-949.
27. Poller DN, Silverstein MJ, Galea M, et al. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification, association between cellular proliferation and c-erbB-2 protein expression, Mod. Pathol. 1994;7:257-262.
28. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N. Engl. J. Med. 1997;337:956-962.
29. Rajan PB, Scott DJ, Perry RH, Griffith CD. P53 protein expression in ductal carcinoma in situ (DCIS) of the breast. Breast Cancer Res. Treat. 1997;42(3):283-290.
30. Recht A, van Dongen JA, Fentiman IS, Holland R, Peterse JL. Third meeting of the DCIS working party of the EORTC - conference report. Eur. J. Cancer 1994;30A:1895-1901.
31. Rosai J. Borderline epithelial lesions of the breast. Am. J. Surg. Pathol. 1991;15(3):209-221.
32. Schnitt SJ, Silen W, Sadowsky NS, Connolly JL, Harris JR. Ductal carcinoma in situ (intraductal carcinoma) of the breast. N. Engl. J. Med. 1990;318:898-903.
33. Schwartz GF, Finkel GC, Garcia JC, Patchefsky AS. Subclinical ductal carcinoma in situ of the breast: treatment by local excision and surveillance alone. Cancer 1992;70:2468-2474.
34. Sicinski P, Donaher JL, Parker SB, et al. Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 1995;82:621-630.
35. Silverstein MJ. Van Nuys experience by treatment. In: Silverstein MJ, editor. Ductal carcinoma in situ of the breast, vol. 47. Baltimore, MD: Williams and Wilkins, 1997. pp. 443-448.
36. Silvestrini R, Veneroni S, Benini E, et al. Expression of p53. Glutathione S-transferase- , and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer, J. Natl. Cancer Inst. 1997;89(9):639-645.
37. Simpson JF, Quan DE, O'Malley F, Odom-Maryon T, Clarke PE. Amplification of CCND1 and expression of its protein product, cyclin D1, in ductal carcinoma in situ of the breast, Am. J. Pathol. 1997; 151(1):161-168.
38. Siziopikou KP, Prioleau JE, Harris JR, Schnitt SJ. Bcl-2 expression in the spectrum of preinvasive breast cancer. Cancer 1996;77(3):499-506.
39. Sjögren S, Inganäs M, Norberg T, et al. The p53 gene in breast cancer: prognostic value of complementary DANN sequencing versus immunohistochemistry, . J. Natl. Cancer Inst. 1996;88(3/4):173-182.
40. Solin LJ, Yeh IT, Kurtz J, et al. Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast conserving surgery and definitive irradiation. Correlation of pathological parameters with outcome of treatment, Cancer 1993;71:2532-2542.
41. Steeg PS, Zhou Q. Cyclins and breast cancer. Breast Cancer Res. Treat. 1998;52:17-28.
42. Strom E, Bassett LW, Dershaw DD, Fowble B, Harris JR, Wilson JF. Amercian College of Radiology. Standards 1997:273-290.
43. Sukumar S, McKenzie K, Chen Y. Animal models for breast cancer. Mutat. Res. 1995;333:37-44.
44. Thor AD, Moore DH, Edgerton SM. et al., Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancer, J. Natl. Cancer Inst. 1992;84:845-855.
45. Thor AD, Berry DA, Budman DR, et al. ErbB-2, p53 and efficacy of adjuvant therapy in lymph node-positive breast cancer, . J. Natl. Cancer Inst. 1998;90(18):1346-1360.
46. Van de Vijver MJ. Ductal carcinoma in situ of the breast: histological classification and genetic alterations, In: Adjuvant therapy of primary breast cancer VI, Berlin, Germany: Springer, 1998.
47. Vos CB, Ter-Harr NT, Peterse JL, Cornelisse CJ, van de Vijer MJ. Cyclin D1 gene amplification and overexpression are present in ductal carcinoma in situ of the breast, . J. Pathol. 1999;187:279-284.
48. Weinstat-Salow D, Merino MJ, Manrow RE, et al. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinoma from non-malignant lesions. Nat. Med. 1995;1:1257-1260.
49. Zhang SY, Caamano J, Cooper F, Guo X, Klein-Szanto JP. Immunohistochemistry of cyclin D1 in human breast cancer. Am. J. Clin. Pathol. 1994;102:695-698.